Occurrence of medullary thyroid carcinoma, bronchial carcinoid tumor, and papillary thyroid carcinoma in a family bearing the RET G691S polymorphism

Journal of Endocrinological Investigation

Volumn 32, Issue 2, 2009, Pages 115-118

  Rotondi, M ^a   Ercolino, T ^b   Fonte, R ^a   Lagonigro, M S ^a   Leporati, P ^a   Villan, L ^c   La Manna, L ^d   Mannelli, M ^b   Chiovato, L ^a,d  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF FLORENCE   (Italy)

^c Department of Pathology ^*

^d IRCCS   (Italy)

Author keywords

Carcinoid; G691S polymorphism; Neuroendocrine tumors; RET; Thyroid Cancer

Indexed keywords

CALCITONIN; PENTAGASTRIN;

ADULT; AGED; ARTICLE; AUTOIMMUNE THYROIDITIS; BRONCHUS CARCINOID; CANCER THERAPY; CASE REPORT; CODON; COMPUTER ASSISTED TOMOGRAPHY; EXON; FEMALE; GENETIC ANALYSIS; GENETIC POLYMORPHISM; HUMAN; MALE; MISSENSE MUTATION; NEUROENDOCRINE TUMOR; NODULAR GOITER; THORAX RADIOGRAPHY; THYROID CARCINOMA; THYROID MEDULLARY CARCINOMA; THYROIDECTOMY;

EID: 67649337169     PISSN: 03914097     EISSN: None     Source Type: Journal    
DOI: 10.1007/BF03345698     Document Type: Article

References (20)

1. th ed. Philadelphia: WB Saunders. 2003, 1857-76.
2. Modlin IM, Lye KD, Kidd M. A 5-decade analysis of 13,715 carcinoid tumors. Cancer 2003, 97: 934-59.
3. Fialkowski EA, Moley JF. Current approaches to medullary thyroid carcinoma, sporadic and familial. J Surg Oncol 2006, 94: 737-47.
4. Murakurrio Y, Jijiwa M, Asai N, Ichihara M, Takahashi M. RET and neuroendocrine tumors. Pituitary 2006, 9: 179-92.
5. Plaza-Menacho I, Burzynski GM, de Groot JW, Eggen BJ, Hofstra RM. Current concepts in RET-related genetics, signaling and therapeutics. Trends Genet 2006, 22: 627-36.
6. De Groot JW, Links TP, Plukker JT, Lips CJ, Hofstra RM. RET as a diagnostic and therapeutic target in sporadic and hereditary endocrine tumors. Endocr Rev 2006, 27: 535-60.
7. Arighi E, Borrello MG, Sariola H. RET tyrosine kinase signaling in development and cancer. Cytokine Growth Factor Rev 2005, 16: 441-67.
8. Elisei R, Cosci B, Romei C, et al. Prognostic significance of somatic RET oncogene mutations in sporadic medullary thyroid cancer: a 10-year follow-up study. J Clin Endocrinol Metab 2008, 93: 682-7.
9. Robledo M, Gil L, Pollán M, et al. Polymorphisms G691S/S904S of RET as genetic modifiers of MEN 2A. Cancer Res 2003, 63: 1814-7.
10. Pacini F, Fontanelli M, Fugazzola L, et al. Routine measurement of serum calcitonin in nodular thyroid diseases allows the preoperative diagnosis of unsuspected sporadic rnedullary thyroid carcinoma. J Clin Endocrinol Metab 1994, 78: 826-9.
11. Boi F, Maurelli I, Pinna G, et al. Calcitonin measurement in washout fluid from fine needle aspiration of neck masses in patients with primary and metastatic medullary thyroid carcinoma. J Clin Endocrinol Metab 2007, 92: 2115-8.
12. Sachithanandan N, Harle RA, Burgess JR. Bronchopulmonary carcinoid in multiple endocrine neoplasia type 1. Cancer 2005, 103: 509-15.
13. Ichihara M, Murakumo Y, Takahashi M. RET and neuroendocrine tumors. Cancer Lett 2004, 204: 197-211.
14. Santoro M, Carlomagno F, Melillo RM, FuscoA. Dysfunction of the RET receptor in human cancer. Cell Mol Life Sci 2004, 61: 2954-64.
15. Weber F, Eng C. Editorial: germline variants within RET: Clinical utility or scientific playtoy? J Clin Endocrinol Metab 2005, 90: 6334-6.
16. Elisei R, Cosci B, Romei C, et al. RET exon 11 (G6915) polymorphism is significantly more frequent in sporadic medullary thyroid carcinoma than in the general population. J Clin Endocrinol Metab 2004, 89: 3579-84.
17. Gursoy A, Erdogan ME, Erdogan G. Significance of the RET proto oncogene polymorphisms in Turkish sporadic medullary thyroid carcinoma patients. J Endocrinol Invest 2006, 29: 858-62.
18. Lönn S, Bhatti P, Alexander BH, et al. Papillary thyroid cancer and polymorphic variants in TSHR-ano RET-related genes: a nested case-control study within a cohort of U.S. radiologic technologists. Cancer Epidemiol Biomarkers Prey 2007, 16: 174-7.
19. Lesueur F, Cebrian A, Robledo M, et al. Polymorphisms in RET and its coreceptors and ligands as genetic modifiers of multiple endocrine neoplasia type 2A. Cancer Res 2006, 66: 1177-80.
20. Sawai H, Okada Y, Kazanjian K, et al. The G691S RET polymorphism increases glial cell line-derived neurotrophic factor-induced pancreatic cancer cell invasion by amplifying mitogen-activated protein kinase signaling. Cancer Res 2005, 65: 11536-44.